Cắt bỏ di căn và tái phát cục bộ của ung thư biểu mô tế bào thận sau liệu pháp nhắm mục tiêu trước phẫu thuật: xác suất kiểm soát cục bộ hoàn toàn và kết quả

Siegel R, Ma J, Zou Z, Jema A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.3109/21681805.2013.864698 Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269 Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100(4):755–759 Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal-cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561 Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882 Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181(5):2044–2051 Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B (2012) Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30(5):482–487 Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA (2015) Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 194(2):316–322. doi:10.1016/j.juro.2015.02.2943 Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16(6):2261–2266 Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937 Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG (2011) Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10–15 Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG (2011) Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273–1279 Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180:94–98 Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444 Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102(6):692–696 Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S (2009) Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 55(1):237–239 O’Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W III, Pili R, Schwaab T (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78(3):595–600 US National Institutes of Health (2010) Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. http://clinicaltrials.gov/ct2/show/NCT01099423. Last Accessed 5 May 2010. Clinical Trials gov Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4):533–539 Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076–4081 Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A (2013) Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 81(1):111–115 Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O’Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A (2011) The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 60(3):448–454